{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T07:14:59Z","timestamp":1791875699645,"version":"4.3.4"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T00:00:00Z","timestamp":1748044800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"New Zealand Society of Gastroenterology"},{"DOI":"10.13039\/501100001232","name":"Royal Australasian College of Physicians","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001232","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Inflammatory bowel disease (IBD) is a relapsing-remitting illness requiring proactive monitoring of gut inflammation. We aimed to determine the correlations of plasma myeloperoxidase (pMPO) and calprotectin (pCal), two neutrophil proteins, with existing measures of disease activity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adults with IBD undergoing ileocolonoscopy were recruited prospectively. Baseline assessments included blood tests (pMPO, pCal, and C-reactive protein ([CRP]), symptom questionnaires, and endoscopic indices (simple endoscopic score for CD [SES-CD] and UC endoscopic index of severity [UCEIS]). Active IBD was defined as SES-CD\u2005&amp;gt;\u20052 and UCEIS\u2005\u2265\u20052. Spearman\u2019s rank correlations assessed the associations between blood markers and endoscopic activity. The area under the receiver operating characteristics curves (AUROC) and univariable logistic regression assessed the ability of blood markers (at optimal thresholds) to identify active disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 170 participants were included (female, n\u2005=\u200592; Crohn\u2019s disease [CD], n\u2005=\u200599; median age 46 years, IQR 35-58). Plasma biomarkers more accurately identified active IBD in individuals with UC (AUROCpMPO\u2005=\u20050.76, P\u2005&amp;lt;\u2005.001; AUROCpCal\u2005=\u20050.66, P\u2005&amp;lt;\u2005.05; AUROCCRP\u2005=\u20050.73, P\u2005&amp;lt;\u2005.001) than in CD (AUROCpMPO\u2005=\u20050.62, P\u2005&amp;gt;\u2005.05; AUROCpCal\u2005=\u20050.65, P\u2005&amp;lt;\u2005.01; AUROCCRP\u2005=\u20050.66, P\u2005&amp;lt;\u2005.01). In all patients with IBD, the addition of pCal (AUROC\u2005=\u20050.73, P\u2005&amp;lt;\u2005.001) and pMPO (AUROC\u2005=\u20050.73, P\u2005&amp;lt;\u2005.001) to CRP added benefit compared to CRP (AUROC\u2005=\u20050.70, P\u2005&amp;lt;\u2005.001) alone. Plasma myeloperoxidase\u2005&amp;gt;\u200513.86\u00a0ng\/mL (odds ratio [OR]\u2005=\u200510.13, 3.4-30.16) and pCal\u2005&amp;gt;\u2005961.72\u00a0ng\/mL (OR\u2005=\u20053.38, 1.21-9.4) were associated with an increased odds of having endoscopically active UC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Plasma MPO shows promise as a potential blood-based biomarker of IBD activity, especially in UC. The combined use of pMPO and CRP adds diagnostic utility in discriminating between active versus quiescent IBD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ibd\/izaf110","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T07:41:57Z","timestamp":1745826117000},"page":"3003-3010","source":"Crossref","is-referenced-by-count":11,"title":["Plasma Calprotectin and Myeloperoxidase as Biomarkers in Inflammatory Bowel Disease"],"prefix":"10.1093","volume":"31","author":[{"given":"Duo","family":"Hou","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Otago Christchurch , Christchurch ,","place":["New Zealand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1954-844X","authenticated-orcid":false,"given":"Akhilesh","family":"Swaminathan","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Otago Christchurch , Christchurch ,","place":["New Zealand"]},{"name":"Department of Gastroenterology , Christchurch Hospital, Christchurch ,","place":["New Zealand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace M","family":"Borichevsky","sequence":"additional","affiliation":[{"name":"M\u0101tai H\u0101ora - Centre for Redox Biology and Medicine, Department of Pathology and Biomedical Science, University of Otago Christchurch , Christchurch ,","place":["New Zealand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris M","family":"Frampton","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Otago Christchurch , Christchurch ,","place":["New Zealand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8218-7766","authenticated-orcid":false,"given":"Antony J","family":"Kettle","sequence":"additional","affiliation":[{"name":"M\u0101tai H\u0101ora - Centre for Redox Biology and Medicine, Department of Pathology and Biomedical Science, University of Otago Christchurch , Christchurch ,","place":["New Zealand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2298-5141","authenticated-orcid":false,"given":"Richard B","family":"Gearry","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Otago Christchurch , Christchurch ,","place":["New Zealand"]},{"name":"Department of Gastroenterology , Christchurch Hospital, Christchurch ,","place":["New Zealand"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,24]]},"reference":[{"issue":"9573","key":"2025112116471198600_CIT0001","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/S0140-6736(07)60750-8","article-title":"Inflammatory bowel disease: cause and immunobiology","volume":"369","author":"Baumgart","year":"2007","journal-title":"Lancet."},{"issue":"5","key":"2025112116471198600_CIT0002","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology."},{"issue":"4","key":"2025112116471198600_CIT0003","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/mi.2012.24","article-title":"The role of neutrophils during intestinal inflammation","volume":"5","author":"Fournier","year":"2012","journal-title":"Mucosal Immunol"},{"issue":"2","key":"2025112116471198600_CIT0004","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1042\/bj2520529","article-title":"Superoxide modulates the activity of myeloperoxidase and optimizes the production of hypochlorous acid","volume":"252","author":"Kettle","year":"1988","journal-title":"Biochem J."},{"issue":"12","key":"2025112116471198600_CIT0005","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1093\/ecco-jcc\/jjac098","article-title":"Faecal myeloperoxidase as a biomarker of endoscopic activity in inflammatory bowel disease","volume":"16","author":"Swaminathan","year":"2022","journal-title":"J Crohns Colitis."},{"issue":"3","key":"2025112116471198600_CIT0006","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1097\/MEG.0b013e32832bab49","article-title":"Fecal calprotectin is a predictive marker of relapse in Crohn\u2019s disease involving the colon: a prospective study","volume":"22","author":"Kallel","year":"2010","journal-title":"Eur J Gastroenterol Hepatol."},{"issue":"3","key":"2025112116471198600_CIT0007","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1097\/MIB.0000000000000652","article-title":"Low fecal calprotectin correlates with histological remission and mucosal healing in ulcerative colitis and colonic Crohn\u2019s disease","volume":"22","author":"Zittan","year":"2016","journal-title":"Inflamm Bowel Dis."},{"issue":"40","key":"2025112116471198600_CIT0008","doi-asserted-by":"publisher","first-page":"11469","DOI":"10.3748\/wjg.v21.i40.11469","article-title":"Are faecal markers good indicators of mucosal healing in inflammatory bowel disease","volume":"21","author":"Boon","year":"2015","journal-title":"World J Gastroenterol."},{"issue":"11","key":"2025112116471198600_CIT0009","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1136\/jclinpath-2012-200901","article-title":"Faecal markers of gastrointestinal inflammation","volume":"65","author":"Sherwood","year":"2012","journal-title":"J Clin Pathol."},{"issue":"36","key":"2025112116471198600_CIT0010","doi-asserted-by":"publisher","first-page":"5584","DOI":"10.3748\/wjg.14.5584","article-title":"Fecal markers of inflammation used as surrogate markers for treatment outcome in relapsing inflammatory bowel disease","volume":"14","author":"Wagner","year":"2008","journal-title":"World J Gastroenterol."},{"issue":"12","key":"2025112116471198600_CIT0011","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1002\/ibd.22917","article-title":"Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease","volume":"18","author":"D\u2019Haens","year":"2012","journal-title":"Inflamm Bowel Dis."},{"issue":"6","key":"2025112116471198600_CIT0012","doi-asserted-by":"publisher","first-page":"E80","DOI":"10.1097\/MIB.0b013e31828dc6d3","article-title":"Fecal calprotectin does not predict endoscopic remission in inflammatory bowel disease","volume":"19","author":"Falvey","year":"2013","journal-title":"Inflamm Bowel Dis."},{"issue":"6","key":"2025112116471198600_CIT0013","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1053\/j.gastro.2010.11.058","article-title":"The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease","volume":"140","author":"Lewis","year":"2011","journal-title":"Gastroenterology."},{"issue":"3","key":"2025112116471198600_CIT0014","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1053\/j.gastro.2019.10.034","article-title":"Development and validation of a test to monitor endoscopic activity in patients with Crohn\u2019s disease based on serum levels of proteins","volume":"158","author":"D\u2019Haens","year":"2020","journal-title":"Gastroenterology."},{"issue":"5","key":"2025112116471198600_CIT0015","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1097\/MIB.0000000000000671","article-title":"Comparison of fecal inflammatory markers in Crohn\u2019s disease","volume":"22","author":"Wright","year":"2016","journal-title":"Inflamm Bowel Dis."},{"issue":"7","key":"2025112116471198600_CIT0016","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1111\/imj.15298","article-title":"Patient perceptions of current and potential inflammatory bowel disease diagnostic and monitoring tests","volume":"52","author":"Ho","year":"2022","journal-title":"Intern Med J."},{"issue":"12","key":"2025112116471198600_CIT0017","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1080\/00365521.2018.1527394","article-title":"Patients\u2019 perceptions of faecal calprotectin testing in inflammatory bowel disease: results from a prospective multicentre patient-based survey","volume":"53","author":"Kalla","year":"2018","journal-title":"Scand J Gastroenterol."},{"issue":"8","key":"2025112116471198600_CIT0018","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1097\/MIB.0000000000001140","article-title":"Comparative acceptability and perceived clinical utility of monitoring tools: a nationwide survey of patients with inflammatory bowel disease","volume":"23","author":"Buisson","year":"2017","journal-title":"Inflamm Bowel Dis."},{"issue":"8167","key":"2025112116471198600_CIT0019","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/s0140-6736(80)92767-1","article-title":"A simple index of Crohn\u2019s disease activity","volume":"1","author":"Harvey","year":"1980","journal-title":"Lancet."},{"issue":"1","key":"2025112116471198600_CIT0020","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/gut.43.1.29","article-title":"A simple clinical colitis activity index","volume":"43","author":"Walmsley","year":"1998","journal-title":"Gut."},{"issue":"12","key":"2025112116471198600_CIT0021","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1002\/ibd.21300","article-title":"Endoscopic evaluation of Crohn\u2019s disease activity: comparison of the CDEIS and the SES-CD","volume":"16","author":"Sipponen","year":"2010","journal-title":"Inflamm Bowel Dis."},{"issue":"5","key":"2025112116471198600_CIT0022","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1053\/j.gastro.2013.07.024","article-title":"Reliability and initial validation of the ulcerative colitis endoscopic index of severity","volume":"145","author":"Travis","year":"2013","journal-title":"Gastroenterology."},{"issue":"4","key":"2025112116471198600_CIT0023","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/s0016-5107(04)01878-4","article-title":"Development and validation of a new, simplified endoscopic activity score for Crohn\u2019s disease: the SES-CD","volume":"60","author":"Daperno","year":"2004","journal-title":"Gastrointest Endosc."},{"issue":"4","key":"2025112116471198600_CIT0024","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1136\/gutjnl-2011-300486","article-title":"Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS)","volume":"61","author":"Travis","year":"2012","journal-title":"Gut."},{"issue":"1","key":"2025112116471198600_CIT0025","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1&lt;32::aid-cncr2820030106&gt;3.0.co;2-3","article-title":"Index for rating diagnostic tests","volume":"3","author":"Youden","year":"1950","journal-title":"Cancer."},{"issue":"3","key":"2025112116471198600_CIT0026","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2307\/2531595","article-title":"Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach","volume":"44","author":"DeLong","year":"1988","journal-title":"Biometrics."},{"issue":"11","key":"2025112116471198600_CIT0027","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1016\/j.cgh.2008.06.010","article-title":"Relationships between disease activity and serum and fecal biomarkers in patients with Crohn\u2019s disease","volume":"6","author":"Jones","year":"2008","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"6","key":"2025112116471198600_CIT0028","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/ajg.2015.120","article-title":"C-Reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: a systematic review and meta-analysis","volume":"110","author":"Mosli","year":"2015","journal-title":"Am J Gastroenterol."},{"issue":"10","key":"2025112116471198600_CIT0029","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1111\/apt.17956","article-title":"Review article: telecare in gastroenterology-within the COVID-19 pandemic and beyond","volume":"59","author":"Hakak","year":"2024","journal-title":"Aliment Pharmacol Ther."},{"issue":"7152","key":"2025112116471198600_CIT0030","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/nature06005","article-title":"Unravelling the pathogenesis of inflammatory bowel disease","volume":"448","author":"Xavier","year":"2007","journal-title":"Nature."},{"issue":"1","key":"2025112116471198600_CIT0031","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3748\/wjg.v20.i1.91","article-title":"Inflammatory bowel disease: pathogenesis","volume":"20","author":"Zhang","year":"2014","journal-title":"World J Gastroenterol."},{"issue":"1","key":"2025112116471198600_CIT0032","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/13510002.1997.11747085","article-title":"Myeloperoxidase: a key regulator of neutrophil oxidant production","volume":"3","author":"Kettle","year":"1997","journal-title":"Redox Report"},{"key":"2025112116471198600_CIT0033","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.abb.2018.03.012","article-title":"Myeloperoxidase in the inflamed colon: a novel target for treating inflammatory bowel disease","volume":"645","author":"Chami","year":"2018","journal-title":"Arch Biochem Biophys."},{"issue":"6","key":"2025112116471198600_CIT0034","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1111\/apt.18154","article-title":"Faecal biomarkers for diagnosis and prediction of disease course in treatment-na\u00efve patients with IBD","volume":"60","author":"Ling Lundstr\u00f6m","year":"2024","journal-title":"Aliment Pharmacol Ther."},{"issue":"1","key":"2025112116471198600_CIT0035","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1093\/ibd\/izae032","article-title":"Comparison of fecal calprotectin and myeloperoxidase in predicting outcomes in inflammatory bowel disease","volume":"31","author":"Swaminathan","year":"2024","journal-title":"Inflamm Bowel Dis."},{"issue":"1","key":"2025112116471198600_CIT0036","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1136\/gut.35.1.77","article-title":"Interrelations between interleukin-6, interleukin-1 beta, plasma C-reactive protein values, and in vitro C-reactive protein generation in patients with inflammatory bowel disease","volume":"35","author":"Mazlam","year":"1994","journal-title":"Gut."},{"issue":"10","key":"2025112116471198600_CIT0037","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1136\/gutjnl-2021-324855","article-title":"Calprotectin: from biomarker to biological function","volume":"70","author":"Jukic","year":"2021","journal-title":"Gut."},{"issue":"10","key":"2025112116471198600_CIT0038","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1080\/00365521.2019.1665097","article-title":"Plasma calprotectin is superior to serum calprotectin as a biomarker of intestinal inflammation in ulcerative colitis","volume":"54","author":"Malham","year":"2019","journal-title":"Scand J Gastroenterol."}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izaf110\/63328633\/izaf110.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/31\/11\/3003\/63328633\/izaf110.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/31\/11\/3003\/63328633\/izaf110.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T21:47:18Z","timestamp":1763761638000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/31\/11\/3003\/8145488"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,24]]},"references-count":38,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,5,24]]},"published-print":{"date-parts":[[2025,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izaf110","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,5,24]]}}}